Exicure, Bluejay Therapeutics enter into patent license pact

Exicure and Bluejay Therapeutics announced they entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis. Under the terms of the agreement, Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of this Agreement. Exicure will also be entitled to modest royalties on future net sales on all licensed technology by Bluejay during the term of the licensed patents. Exicure will be responsible for, and make all decisions concerning, the preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.